[1] Fan J G, Xu X Y, Nan Y M, et al. Guidelines for Prevention and treatment of metabolic (non-alcoholic) fatty liver disease (2024 edition)[J]. J Clin Hepatol,2024,27(4):494-510.
[2] Tacke F, Horn P, Wong V W S, et al. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol,2024.
[3] Eslam M, Sarin S K, Wong V W S, et al. The Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int,2020,14:889-919.
[4] Díaz L A, Arab J P, Louvet A, et al. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol,2023,20(12):764-783.
[5] Åberg F, Puukka P, Salomaa V, et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease[J]. Clin Gastroenterol Hepatol,2019,18(4):995-997.e2.
[6] Åberg F, Färkkilä M. Drinking and obesity: alcoholic liver disease/nonalcoholic fatty liver disease interactions[J]. Semin Liver Dis,2020,40(2):154-162.
[7] Sun D Q, Targher G, Byrne C D, et al. An international Telphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease[J]. Hepatobiliary Surg Nutr,2023,12(3):386.
[8] Hashida R, Golabi P, Ong J, et al. Alcohol and metabolic syndrome interaction[J]. Clin Liver Dis,2024,28(4):601-620.
[9] Åberg F, Puukka P, Salomaa V, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts[J]. Hepatology,2020,71(3):835-848.
[10] Zhao Y, Yuan X, Lin T, et al. Combined impact of alcohol consumption and metabolic syndrome on liver dysfunction in an elderly Chinese population[J]. Diabetol Metab Syndr,2024,16(1):74.
[11] Younossi Z M, Stepanova M, Ong J, et al. Effects of alcohol consumption and metabolic syndrome on mortality in patients with nonalcoholic and alcohol-related fatty liver disease[J]. Clin Gastroenterol Hepatol,2019,17(8):1625-1633.e1.
[12] Åberg F, Färkkilä M, Männistö V. Interaction between alcohol use and metabolic risk factors for liver disease: a critical review of epidemiological studies[J]. Alcohol Clin Exp Res,2020,44(2):384-403.
[13] Israelsen M, Torp N, Johansen S, et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study[J]. Lancet Gastroenterol Hepatol,2024,9(3):218-228.
[14] Ciardullo S, Mantovani A, Morieri M L, et al. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence[J]. Liver Int,2024.
[15] Kwak M, Kim H, Jiang Z G, et al. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: a population based study with 26.7 years of follow-up[J]. Hepatology,2024.
[16] Marti-Aguado D, Calleja J L, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease[J]. J Hepatol,2024.
[17] Baik I, Shin C. Prospective study of alcohol consumption and metabolic syndrome[J]. Am J Clin Nutr,2008,87(5):1455-1463.
[18] Choi S, Kim K, Lee J K, et al. Association between change in alcohol consumption and metabolic syndrome: analysis from the health examinees study[J]. Diabetes Metab J,2019,43(5):615-626.
[19] Chang Y, Ryu S, Kim Y, et al. Low levels of alcohol consumption, obesity, and development of fatty liver with and without evidence of advanced fibrosis[J]. Hepatology,2020,71(3):861-873.
[20] Llamosas-Falcón L, Rehm J, Bright S, et al. The relationship between alcohol consumption, BMI, and type 2 diabetes: a systematic review and dose-response meta-analysis[J]. Diabetes Care,2023,46(11):2076-2083.
[21] Ding C, O′Neill D, Bell S, et al. Association of alcohol consumption with morbidity and mortality in patients with cardiovascular disease: original data and meta-analysis of 48,423 men and women[J]. BMC Med,2021,19:1-14.
[22] Wong R J, Yang Z, Cheung R, et al. Impact of longitudinal alcohol use patterns on long-term risk of cirrhosis among US Veterans with steatotic liver disease[J]. Gastroenterology,2024,166(6):1156-1165.e4.
[23] Duell P B, Welty F K, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association[J]. Arterioscler Thromb Vasc Biol,2022,42(6):e168-e185.
[24] Israelsen M, Kim M, Suvitaival T, et al. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication[J]. JHEP Rep,2021,3(5):100325.
[25] Thoudam T, Chanda D, Lee J Y, et al. Enhanced Ca2+-channeling complex formation at the ER-mitochondria interface underlies the pathogenesis of alcohol-associated liver disease[J]. Nat Commun,2023,14(1):1703.
[26] Flashner S, Shimonosono M, Tomita Y, et al. ALDH2 dysfunction and alcohol cooperate in cancer stem cell enrichment[J]. Carcinogenesis,2024,45(1-2):95-106.
[27] Costentin C E, Minoves M, Kotzki S, et al. Alcohol-related hepatocellular carcinoma is a heterogenous condition: lessons from a latent class analysis[J]. Liver Int,2022,42(7):1638-1647.
[28] Li M, Xie W. Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?[J]. J Hepatol,2024,80(2):e53-e54.
[29] Huang D Q, Tan D J H, Ng C H, et al. Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis[J]. Clin Gastroenterol Hepatol,2023,21(5):1169-1177.
[30] Ding C, Ng Fat L, Britton A, et al. Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease[J]. Nat Commun,2023,14(1):8041.
[31] Lim J, Kim S E, Jo A J, et al. Effect of diabetes on mortality and liver transplantation in alcoholic liver cirrhotic patients with acute decompensation[J]. Hepatol Int,2024.
[32] Ioannou G N, Green P, Kerr K F, et al. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification[J]. J Hepatol,2019,71(3):523-533.
[33] Parker R, Kim S J, Im G Y, et al. Obesity in acute alcoholic hepatitis increases morbidity and mortality[J]. EBioMedicine,2019,45:511-518.
[34] Floris A, Chandla S, Lim Y, et al. Sumoylation of methionine adenosyltransferase alpha 1 promotes mitochondrial dysfunction in alcohol-associated liver disease[J]. Hepatology,2024,80(1):102-118.
[35] Inan-Eroglu E, Huang B H, Ahmadi M N, et al. Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank[J]. Eur J Clin Nutr,2022,76(1):74-83. |
